Screening for cognitive toxicity of anticholinergic drugs.
Impairment of memory by muscarinic anticholinergic drugs has been demonstrated with a variety of agents using both acute administration in normal volunteers and chronic treatment in patients. Cognitive toxicity must be considered in the evaluation of the risks versus the benefits of psychopharmacologic treatment. The relationship between serum levels of anticholinergic drugs measured by radioreceptor assay and performance on the Buschke Selective Reminding Test were investigated to develop strategies for identifying patients with drug-related cognitive impairment. The radioreceptor assay may be of value in screening for patients at high risk for cognitive toxicity. However, there appears to be no alternative to careful longitudinal evaluation of learning and memory in patients after appropriate trial modifications of their medication regimens to identify patients with drug-related impairment.
Katz
I R
IR
Greenberg
W M
WM
Barr
G A
GA
Garbarino
C
C
Buckley
P
P
Smith
D
D
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000097:blood; D001285:Atropine / Q000009:adverse effects / Q000097:blood; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000139:chemically induced; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects / Q000097:blood*; D011581:Psychological Tests; D011869:Radioligand Assay; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy
D014150:Antipsychotic Agents; D010276:Parasympatholytics; D001285:Atropine